Alnylam Pharmaceuticals Inc. (ALNY) Given a $145.00 Price Target at Credit Suisse Group AG
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) received a $145.00 price target from equities researchers at Credit Suisse Group AG in a research report issued to clients and investors on Friday. The firm presently has a a “buy” rating on the biopharmaceutical company’s stock. Credit Suisse Group AG’s price target would indicate a potential upside of 113.93% from the stock’s current price.
Several other brokerages have also weighed in on ALNY. Jefferies Group reissued a “buy” rating and set a $80.00 price objective (down previously from $119.00) on shares of Alnylam Pharmaceuticals in a report on Wednesday, June 8th. Zacks Investment Research lowered Alnylam Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, July 25th. FBR & Co reissued an “outperform” rating and set a $180.00 price objective on shares of Alnylam Pharmaceuticals in a report on Tuesday, September 27th. Morgan Stanley set a $93.00 price target on Alnylam Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, September 6th. Finally, Chardan Capital reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Monday, July 11th. Three analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $110.14.
Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) traded down 1.84% on Friday, hitting $66.53. The stock had a trading volume of 326,338 shares. The firm has a 50 day moving average price of $73.32 and a 200-day moving average price of $66.22. Alnylam Pharmaceuticals has a 52 week low of $49.96 and a 52 week high of $110.75. The company’s market cap is $5.70 billion.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($1.05) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.24) by $0.19. Alnylam Pharmaceuticals had a negative return on equity of 29.60% and a negative net margin of 1,204.91%. The company had revenue of $8.70 million for the quarter, compared to analyst estimates of $8.09 million. During the same quarter last year, the firm earned ($0.85) EPS. Alnylam Pharmaceuticals’s revenue for the quarter was up .2% compared to the same quarter last year. Analysts anticipate that Alnylam Pharmaceuticals will post ($4.64) EPS for the current year.
In related news, CEO John Maraganore sold 30,151 shares of the company’s stock in a transaction dated Wednesday, July 20th. The stock was sold at an average price of $64.69, for a total value of $1,950,468.19. Following the completion of the sale, the chief executive officer now owns 148,465 shares in the company, valued at $9,604,200.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 4.00% of the stock is owned by corporate insiders.
A number of large investors have recently added to or reduced their stakes in ALNY. Dodge & Cox bought a new stake in Alnylam Pharmaceuticals during the second quarter worth approximately $139,650,000. Wellington Management Group LLP increased its stake in Alnylam Pharmaceuticals by 12.1% in the first quarter. Wellington Management Group LLP now owns 11,945,607 shares of the biopharmaceutical company’s stock worth $749,826,000 after buying an additional 1,288,123 shares in the last quarter. Bridger Management LLC bought a new stake in Alnylam Pharmaceuticals during the first quarter worth approximately $50,041,000. Norges Bank bought a new stake in Alnylam Pharmaceuticals during the fourth quarter worth approximately $56,311,000. Finally, Slate Path Capital LP increased its stake in Alnylam Pharmaceuticals by 56.6% in the first quarter. Slate Path Capital LP now owns 1,135,000 shares of the biopharmaceutical company’s stock worth $71,244,000 after buying an additional 410,000 shares in the last quarter. Institutional investors and hedge funds own 85.96% of the company’s stock.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.
Receive News & Stock Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.